ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullishWuxi Biologics
26 Aug 2023 07:42Broker

WuXi Biologics (2269 HK) – Impressive post-pandemic performance

1H23 revenue impressively beat its previous guidance of low-teens growth, mainly attributable to the strong 59.7% YoY growth of non-COVID revenue.

Logo
369 Views
Share
bullishWuxi Biologics
22 Jun 2023 07:59Broker

WuXi Biologics (2269 HK) – 2023E growth outlook remains intact

WuXi Bio management maintained its full-year guidance unchanged with revenue growth of 30% YoY and attributable adjusted net income of 26% YoY for...

Logo
285 Views
Share
bullishWuxi Biologics
25 Mar 2023 04:41Broker

WuXi Biologics (2269 HK) – Stronger competency for a brighter future

WuXi Bio reported 2022 revenue of RMB15.3bn, up 48.4% YoY, and attributable adjusted net income of RMB4.9bn, up 48.5% YoY.

Logo
428 Views
Share
bullishWuxi Biologics
02 Mar 2023 09:06Broker

WuXi Biologics (2269 HK) – Strong and sustainable non-COVID growth

WuXi Bio previously released a positive profit alert for 2022 earnings, expecting revenue to grow ~48.4% YoY, attributable net profit to grow ~30% YoY

Logo
171 Views
Share
23 Nov 2022 07:46Broker

CMBI Research Focus List (November Edition) – Our best high conviction stock ideas

In our last report dated 17 October, we highlighted a list of 21 long ideas.The basket (equal weighted) of these 21 stocks underperformed MSCI...

Logo
287 Views
Share
x